Vulvar and Vaginal Atrophy (VVA) Therapy Market Players:
- Daré Bioscience, Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Almirall, S.A.
- Viveve, Inc.
- Lutronic Corporation
- Venus Concept
- ThermiGen, LLC
- Alma Lasers LTD.
- BTL
- Fotona d.o.o.
- TherapeuticsMD, Inc.
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2026, the industry size of vulvar and vaginal atrophy therapy is assessed at USD 3.18 billion.
The global vulvar and vaginal atrophy therapy market size was valued at more than USD 2.9 billion in 2025 and is expected to register a CAGR of over 10.7%, exceeding USD 8.01 billion revenue by 2035.
North America is set to command the largest share by 2035 in the vulvar and vaginal atrophy (VVA) therapy market, owing to rising cases of hormonal imbalance, vaginal cancers, and growing UTI incidence.
Key players in the market include Daré Bioscience, Inc., Almirall, S.A., Viveve, Inc., Lutronic Corporation, Venus Concept, ThermiGen, LLC, Alma Lasers LTD., BTL, Fotona d.o.o., TherapeuticsMD, Inc, .
